Antiretroviral pharmacology in breast milk

Advances in Experimental Medicine and Biology

Volumn 743, Issue , 2012, Pages 109-118

  Corbett, Amanda H ^a,b  

^a University of North Carolina   (United States)

^b UNIVERSITY OF NORTH CAROLINA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; ATAZANAVIR; EFAVIRENZ; INDINAVIR; LAMIVUDINE; LOPINAVIR; NELFINAVIR; NEVIRAPINE; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; PROTEINASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; ZIDOVUDINE;

ARTICLE; BREAST FEEDING; BREAST MILK; DRUG BLOOD LEVEL; DRUG DETERMINATION; DRUG EXPOSURE; DRUG MILK LEVEL; DRUG PENETRATION; DRUG USE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; IC 50; INFANT NUTRITION; INFECTION PREVENTION; MASS SPECTROMETRY; PRIORITY JOURNAL; VIRUS LOAD; VIRUS REPLICATION; VIRUS RESISTANCE; VIRUS TRANSMISSION;

EID: 84859902598     PISSN: 00652598     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-1-4614-2251-8_8     Document Type: Article

References (42)

1. UNICEF: Child Info: Monitoring the situation of children and women. l http://www.childinfo.org/breastfeeding-challenge.html . Accessed 17 May 2011
2. Mofenson L (2010) Antiretroviral drugs to prevent breastfeeding HIV transmission. Antivir Ther 15:537-553
3. Chasela CS, Hudgens MG, Jaimeson DJ, Kayira D, Hosseinipour M, Kourtis AP et al (2010) Maternal or infant antiretroviral drugs to reduce HIV-1 transmission. N Engl J Med 362:2271-2281
4. The Kesho Bora Study Group (2011) Triple antiretroviral compared with zidovudine and single-dose nevirapine prophylaxis during pregnancy and breastfeeding for prevention of mother-to-child transmission of HIV-1 (Kesho Bora study): a randomized controlled trial. Lancet Infect Dis 11:171-180
5. Kilewo C, Karlsson K, Massawe A, Lyamaya E, Swai A, Mhalu F et al (2008) Prevention of mother-to-child transmission of HIV-1 through breastfeeding by treating infants prophylactically with lamivudine in Dar es Salaam, Tanzania: the Mitra Study. J Acquir Immune Defi c Syndr 48:315-323
6. Kilewo C, Karlsson K, Ngarina M, Massawe A, Lyamuya E, Swai A et al (2009) Prevention of mother-to-child transmission of HIV-1 through breastfeeding by treating mothers with triple antiretroviral therapy in Dar es Salaam, Tanzania: the MITRA PLUS Study. J Acquir Immune Defi c Syndr 52:406-416
7. Kumwenda NI, Hoover DR, Mofenson LM, Thigpen MC, Kafulafula G, Li Q et al (2008) Extended antiretroviral prophylaxis to reduce breast-milk HIV-1 transmission. N Engl J Med 359:119-129
8. Marazzi CM, Germano P, Liotta G, Guidotti G, Loureiro S, Gomes AC et al (2007) Implementing antiretroviral triple therapy to prevent HIV mother-to-child transmission: a public health approach in resource-limited settings. Eur J Pediatr 166:1305-1307
9. Palombi L, Marazzi MC, Voetberg A, Magid NA (2007) Treatment acceleration program and the experience of the DREAM program in prevention of mother-to-child transmission of HIV. AIDS 21(suppl 4):S65-S71
10. Peltier CA, Ndayisaba GF, Lepage P, van Griensven J, Leroy V, Pharm CO et al (2009) Breastfeeding with maternal antiretroviral therapy or formula feeding to prevent HIV postnatal mother to child infection in Rwanda. AIDS 23:2415-2423
11. Shapiro R, Hughes M, Ogwe A, Kitch D, Lockman S, Moffat C et al (2010) Antiretroviral regimens in pregnancy and breastfeeding in Botswana. N Engl J Med 362:2282-2294
12. Six Week Extended-Dose Nevirapine (SWEN) Study Team (2008) Extended-dose nevirapine to 6 weeks of age for infants to prevent HIV transmission via breastfeeding in Ethiopia, India, and Uganda: an analysis of three randomized controlled trials. Lancet 372:300-313
13. Thior I, Lockman S, Smeaton LM, Shapiro RL, Wester C, Heymann SJ et al (2006) Breastfeeding plus infant zidovudine prophylaxis for 6 months vs formula feeding plus infant zidovudine for 1 month to reduce mother-to-child HIV transmission in Botswana: a randomized trial: the Mashi Study. JAMA 296:794-805
14. Thomas TK, Masaba R, Borkowf CB, Ndivo R, Zeh C, Misore A, et al. Triple-antiretroviral prophylaxis to prevent mother-to-child HIV transmission through breastfeeding - the Kisumu Breastfeeding Study, Kenya: a clinical trial. PLoS Med 2011 Mar;8(3):e1001015. Epub 2011 Mar 29
15. Vyankandondera J, Luchters S, Hassink E, Pakker N, Mmiro F, Okong P et al SIMBA-stopping infection from mother to child via breastfeeding in Africa. 3rd international AIDS society conference on HIV pathogenesis. 24-27 July 2003, Paris, France. [Abstract LB07]
16. Begg E, Duffull S, Hackett L, Ilett KF (2002) Studying drugs in human milk: time to unify the approach. J Hum Lact 18:323-343
17. Anderson G (2006) Using pharmacokinetics to predict the effects of pregnancy and maternal-infant transfer of drugs during lactation. Expert Opin Drug Metab Toxicol 2:947-960
18. Dean M, Stock B, Patterson RJ, Levy G (1980) Serum protein binding of drugs during and after pregnancy in humans. Clin Pharmacol Ther 28:253-261
19. Tomson T, Lindbom U, Ekqvist B, Sundqvist A (1994) Epilepsy and pregnancy: a prospective study of seizure control in relation to free and total plasma concentrations of carbamazepine and phenytoin. Epilepsia 35:122-130
20. Yerby MS, Friel PN, McCormick K, Koerner M, van Allen M, Leavitt AM et al (1990) Pharmacokinetics of anticonvulsants in pregnancy: alterations in plasma protein binding. Epilepsy Res 5:223-228
21. Best BM, Stek AM, Mirochnick M, Hu C, Li H, Burchett SK et al (2010) Lopinavir tablet pharmacokinetics with an increased dose during pregnancy. J Acquir Immune Syndr 54:381-388
22. Patterson KB, Dumond JB, Prince HA, Jenkins A, Scarsci K, Wang R et al Pharmacokinetics of the lopinavir/ritonavir tablet in HIV-infected pregnant women: a longitudinal investigation of protein bound and unbound drug exposure with empiric dosage adjustment. 18th conference on retroviruses and opportunistic infections, Feb 2011, Boston, MA
23. Larsen LA, Ito S, Koren G (2003) Prediction of milk/plasma concentration ratio of drugs. Ann Pharmacother 37:1299-1306
24. Atkinson HC, Begg EJ (1990) Prediction of drug distribution into human milk from physiochemical characteristics. Clin Pharmacokinet 18:151-167
25. Notarianni LJ, Belk D, Aird SA, Bennett PN (1995) An in vitro technique for the rapid determination of drug entry into breast milk. Br J Clin Pharmacol 40:333-337
26. Riant P, Urien S, Albengres E, Duche JC, Tillement JP (1986) High plasma protein binding as a parameter in the selection of betablockers for lactating women. Biochem Pharmacol 35:4579-4581
27. da Costa TH, Haisma H, Wells JC, Mander AP, Whitehead RG, Bluck LJ (2010) How much human milk do infants consume? Data from 12 countries using a standardized stable isotope methodology. J Nutr 140:2227-2232
28. Powe CE, Puopolo KM, Newburg DS, Lonnerdal B, Chen C, Allen M et al (2011) Effects of recombinant human prolactin on breast milk composition. Pediatrics 127:e359-e366
29. Rossi DT, Wright DS (1997) Analytical considerations for trace determinations of drugs in breast milk. J Pharm Biomed Anal 15:495-504
30. Rezk N, White N, Bridges A, Abdel-Megeed MF, Mohamed TM, Moselhy SS et al (2008) Studies on antiretroviral drug concentrations in breast milk: validation of a liquid chromatography-tandem mass spectrometric method for determination of 7 anti-human immunodefi ciency virus medications. Ther Drug Monit 30:611-619
31. Bulterys M, Weidle PJ, Abrams EJ, Fowler MG (2005) Combination antiretroviral therapy in African nursing mothers and drug exposure in their infants: new pharmacokinetic and virologic findings. J Infect Dis 192:709-712
32. Colebunders R, Hodossy B, Burger D, Daems T, Roelens K, Coppens M et al (2005) The effect of highly active antiretroviral treatment on viral load and antiretroviral drug levels in breast milk. AIDS 19:1912-1914
33. Corbett A, Martinson F, Rezk N, Kashuba A, Jamieson D, Chasela C et al Antiretroviral drug concentrations in breast milk and breastfeeding infants. 15th conference on retroviruses and opportunistic infections, Feb 2008, Boston, MA [Poster 648]
34. Corbett A, Chasela C, Martinson F, Rezk N, Kashuba A, Jamieson D et al Lopinavir/ritonavir concentrations in breast milk and breastfeeding infants: the BAN study. 16th Conference on retroviruses and opportunistic infections, Feb 2009, Montreal, Canada [Poster T-139]
35. Corbett A, Kayira D, Kashuba A, White N, Kourtis A, Chasela C et al Pharmacokinetics (PK) of HAART in Mothers and Breastfeeding infants from 6-24 wks post partum. 51st interscience conference on antimicrobial agents and chemotherapy, Sep 2010, Boston, MA. [Poster A1-2017]
36. Mirochnick M, Thomas T, Capparelli E, Zeh C, Holland D, Masaba R et al (2009) Antiretroviral concentrations in breast-feeding infants of mothers receiving highly active antiretroviral therapy. Antimicrob Agents Chemother 53:1170-1176
37. Schneider S, Peltier A, Gras A, Arendt V, Karasi-Omes C, Mujawamariwa A et al (2008) Efavirenz in human breast milk, mothers, and newborns plasma. J Acquir Immune Defi c Syndr 48:450-454
38. Shapiro R, Holland D, Capparelli E, Lockman S, Thior I, Wester C et al (2005) Antiretroviral concentrations in breast-feeding infants of women in Botswana receiving antiretroviral treatment. J Infect Dis 192:720-727
39. Spencer L, Neely M, Mordwinkin N, Leon T, Fredericks T, Karim R et al Intensive pharmacokinetics of zidovudine, lamivudine and atazanavir and HIV-1 viral load in breast milk and plasma of HIV + women receiving HAART. 16th conference on retroviruses and opportunistic infections, Feb 2009, Montreal, Canada
40. Salazar-Gonzalez JF, Salazar MG, Learn GH, Fouda GG, Kang HH, Mahlokozera T et al (2011) Origin and evolution of HIV-1 in breast milk determined by single-genome amplifi cation and sequencing. J Virol 85:2751-2763
41. Bennetto-Hood C, Aldrovandi G, King J, Woodman K, Ashouri N, Acosta EP (2007) Persistence of nevirapine in breast milk after discontinuation of treatment. Clin Infect Dis 45:391-394
42. Hudelson SE, McConnell MS, Bagenda D, Piwowar-Manning E, Parsons TL, Nolan ML et al (2010) Emergence and persistence of nevirapine resistance in breast milk after single-dose nevirapine administration. AIDS 24:557-561